Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Will TP53-mutated AML respond to immunotherapy?

Publish date:: November 18, 2019

Key clinical point: New research has shown increased immune infiltration in patients with TP53-mutated acute myeloid leukemia (AML).

Major finding: Patients with TP53-mutated AML had higher levels of T-cell infiltration, immune checkpoint molecules, and interferon-gamma signaling than patients with wild-type TP53.

Study details: Data from a discovery cohort of 147 patients with AML, a validation cohort of 140 patients, and samples from 60 patients with AML.

Disclosures: Dr. Rutella reported research support from NanoString Technologies, MacroGenics, and Kura Oncology.

Citation:

Rutella S et al. SITC 2019, Abstract O3.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,